NICE is urging patients to ask their pharmacist advice about smoking, alcohol or maintaining a healthy weight.
News
Sunosi approved in Europe for EDS in narcolepsy, sleep apnoea
The European Commission has accepted the drug to improve wakefulness and reduce excessive daytime sleepiness in the disorders.
PhoreMost enlists Otsuka in multi-project drug discovery collab
The partnership will have an initial focus on gene therapy applications of identified targets.
NICE rejects Janssen’s Stelara on cost efficiency grounds
The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment.
Darzalex EU nod marks first newly diagnosed MM treatment in six years
The approval was based on results from part one of the Phase III CASSIOPEIA study.
Fight for Sight to fund macular degeneration research
As it stands, damage to the macula can’t be reversed, making it the most common cause of permanent and severe sight loss in the UK.
EU clears Roche’s Polivy for certain lymphomas
The drug has been approved in combination with bendamustine and MabThera.
New scan could see active breast tumour regions in ‘real-time’
Breast cancer is the most common type of cancer in the UK, with around 55,000 new cases each year.
EMA licenses Mayzent for MS
Novartis also expects NICE and SMC decisions in the first half of 2020.
‘Weak antibiotic pipeline’ poses threat to AMR fight
Of the 60 products in development, very few seem to show benefit over existing treatments.
HIV transmissions fall by 71%
The UK is “well on its way towards our ambition of zero HIV transmissions by 2030.”
Heart failure market could surpass ‘$22bn by 2028’
Due to the aging global population, recent years have seen an increased prevalence of chronic HF.
INTCR 2020 closing for entry midnight on Thursday
The 2020 PharmaTimes International Clinical Researcher of the Year will be closing for entry at midnight this Thursday the 23rd of January.
Ibrance given NICE green light in breast cancer
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
Government health commitments just a ‘pipedream’
The plans were “ambitions”, and primary care is not being given the time, support and funding it needs.
